Idorsia (Debt Restructuring)

Funding Details
Awarder
Inbox
Date Award
May 18, 2025
Vertical
Biopharmaceuticals
Funding URL
View Funding Page

Company Info
Traction
Sales of QUVIVIQ (daridorexant) reached CHF 61 million, with projections of approximately CHF 110 million in 2025.
Revenue Amount
$113,000,000
Company Description
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
Market
Healthcare
Location
Allschwil, Switzerland

Links
Back to Home Back to Biopharmaceuticals Deals View Funding Announcement